IPAMORELIN
Ipamorelin is a five-amino-acid growth-hormone secretagogue that activates the ghrelin receptor. Human pharmacology research shows that it can trigger an episode of GH release. The larger recovery, body-composition, muscle and performance story is driven much more by mechanism and community use than by controlled outcome trials.
Ipamorelin signals your body to release more of its own growth hormone, which is why it has become popular for recovery, body composition, sleep and performance.
Limited optimization evidence.
The human evidence establishes pharmacologic activity. It does not yet establish the broad performance and body-composition benefits that dominate community discussion.
A different route into the GH axis.
Ipamorelin is a growth-hormone secretagogue: it activates the ghrelin receptor and stimulates endogenous GH release.
That distinguishes it mechanistically from GHRH analogues such as CJC-1295 and tesamorelin. Early preclinical work characterized ipamorelin as relatively selective for GH release compared with older secretagogues, although that selectivity story should not be mistaken for proof of superior clinical outcomes or safety.
The GH response is demonstrated. The outcomes are not.
A human dose-escalation study evaluated five intravenous infusion levels in healthy male volunteers, with eight subjects at each level. Ipamorelin triggered GH release at every level studied; GH peaked at about 0.67 hours and then declined. The reported terminal half-life of ipamorelin was about two hours.
Ipamorelin was also tested intravenously in a randomized, double-blind, placebo-controlled phase 2 study after bowel resection. Among 114 treated participants, the primary endpoint—time to tolerating a standardized solid meal—was numerically shorter with ipamorelin but was not statistically significant, and secondary GI-recovery endpoints were also not significantly different overall.
The CJC-1295 pairing is part of the story.
In contemporary peptide culture, ipamorelin is frequently discussed as a recovery and body-composition compound and is commonly paired with CJC-1295.
The biological logic is easy to understand: CJC-1295 works through the GHRH pathway, while ipamorelin is a ghrelin-receptor agonist. That complementary mechanism has become a major part of community practice and discussion.
Where the story gets ahead of the data.
MEANINGFUL
Ipamorelin has a measurable human pharmacologic effect: it stimulates GH release. The gap opens when that effect is translated into claims about recovery, sleep, muscle, fat loss and performance—outcomes that have not been tested nearly as well as the hormone response itself.
What people are actually reporting.
Recurring community-use patterns are visible around Ipamorelin. We document those patterns here without turning them into a clinical recommendation.
Community discussions frequently cluster around a few hundred micrograms per administration, especially before bed. Lower amounts around 100 mcg and higher amounts also appear, often when ipamorelin is paired with a GHRH analog.
No FDA-approved ipamorelin dosing protocol exists for body composition, recovery, sleep or “GH optimization.” Human studies demonstrate growth-hormone pharmacology, but that does not validate community dosing for these outcomes. FDA has also flagged safety and characterization concerns for compounded ipamorelin.
Human exposure exists. Important uncertainty remains.
Neither ipamorelin free base nor ipamorelin acetate is a component of an FDA-approved drug. In 2024, FDA evaluated both for possible inclusion on the 503A Bulks List and proposed against inclusion; the advisory committee subsequently voted against placing either substance on the list.
FDA's review identified concerns about immunogenicity, peptide-related impurities and product characterization. In the postoperative trial, adverse-event patterns included higher rates of hypokalemia and hyperglycemia in the ipamorelin arm. Two ipamorelin-treated participants died after postoperative complications; FDA explicitly noted that it was unclear whether those deaths were related to ipamorelin.
Primary evidence behind the profile.
| Evidence | Design | What it adds | What it cannot prove |
|---|---|---|---|
| 1999 · PMID 10496658 | Human dose-escalation PK/PD study | Demonstrated dose-related pharmacokinetics and episodic GH release in healthy male volunteers. | Does not demonstrate recovery, body-composition or performance efficacy. |
| 2014 · PMID 25331030 | Multicenter randomized double-blind placebo-controlled phase 2 study | Tested IV ipamorelin in postoperative bowel-resection patients. | Primary efficacy endpoint was not statistically significant; not an optimization study. |
| FDA · 2024 PCAC review | 503A Bulks List evaluation | Detailed effectiveness, safety and characterization review of ipamorelin free base/acetate. | Compounding-list review is not itself a clinical efficacy trial. |
Compare the GH-axis signals.
CJC-1295
A GHRH analogue with sustained human GH/IGF-1 target engagement—and ipamorelin's best-known community pairing.
Tesamorelin
Compare community-driven GH optimization with a GH-axis peptide supported by randomized outcome trials and an approved indication.
Muscle & Performance
Separate hormone changes from demonstrated improvements in strength, muscle and performance.
What the evidence actually shows.
Growth-hormone release does not establish better sleep or muscle growth
Ipamorelin is a growth-hormone secretagogue. Evidence of hormonal activity or investigation in specialized clinical settings does not demonstrate meaningful improvements in sleep quality, muscle hypertrophy, fat loss, or healthy aging. Products and routes discussed in communities may differ from studied formulations. No FDA-approved ipamorelin product is established here.
Verification source: Evidence interpretation: pharmacodynamic and limited clinical-development findings should be checked against their specific formulation and endpoint before being used to support a benefit claim.
Community Protocol Signal describes unvalidated practices and is not a clinical dosing recommendation.